When to Increase Dolutegravir to Twice Daily Dosing
Increase dolutegravir to 50 mg twice daily when co-administering with rifamycin-containing tuberculosis treatment regimens or when using 1HP (daily rifapentine/isoniazid for 1 month) for latent tuberculosis treatment. 1
Primary Indications for Twice-Daily Dosing
Active Tuberculosis Treatment
- Patients receiving rifampin-containing regimens should receive dolutegravir 50 mg twice daily (evidence rating: AIa) 1
- This applies to all treatment-naïve and treatment-experienced, INSTI-naïve patients
- For pediatric patients, increase to weight-based dosing twice daily
Latent Tuberculosis Treatment with 1HP
- Patients receiving 1HP (daily rifapentine 600 mg + isoniazid 300 mg for 28 days) require dolutegravir 50 mg twice daily (evidence rating: BIa) 1
- Pharmacokinetic data demonstrate that twice-daily dosing maintains adequate trough concentrations above therapeutic thresholds during rifapentine co-administration 2
- 97.7% of participants maintained HIV RNA <50 copies/mL at week 48 with this regimen 1
Important Exception
- Patients receiving 3HP (once-weekly rifapentine + isoniazid for 3 months) can continue standard dolutegravir 50 mg once daily (evidence rating: AIa) 1
- Rifapentine in 3HP decreases dolutegravir exposure by only 26%, but trough concentrations remain above therapeutic thresholds 1
Other Drug Interactions Requiring Twice-Daily Dosing
Metabolic Inducers (per FDA label and guidelines)
Increase to 50 mg twice daily when co-administering with:
These agents reduce dolutegravir exposure by 39-76% through UGT1A1 and CYP3A induction 4, 5.
Critical Caveat for INSTI-Experienced Patients
For patients with INSTI resistance or certain INSTI-associated resistance substitutions:
- Avoid metabolic inducers entirely when possible 1
- The lower dolutegravir exposures with inducers may result in loss of therapeutic effect and development of resistance in this population 3
- If inducers cannot be avoided, use alternative combinations
Drugs That Do NOT Require Dose Adjustment
Standard once-daily dosing is maintained with:
- Atazanavir/ritonavir
- Darunavir/ritonavir
- Rifabutin
- Rilpivirine
- Most other antiretrovirals 3
Practical Monitoring Considerations
While twice-daily dosing increases dolutegravir trough concentrations appropriately during rifamycin co-administration 2, monitor for:
- Viral suppression at weeks 24 and 48
- Adherence challenges with twice-daily regimens
- Return to once-daily dosing after completing tuberculosis treatment
The mechanism underlying dose increase necessity: Rifamycins and other metabolic inducers significantly increase dolutegravir clearance through UGT1A1 and CYP3A induction, reducing drug exposure by 49-76% 4, 5. Twice-daily dosing compensates for this enhanced clearance, maintaining therapeutic trough concentrations above the protein-adjusted IC90.